Breast Cancer Coverage from Every Angle

Javier Cortés, MD, PhD: Clinical Insights on Using Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

Posted: Tuesday, September 28, 2021

Javier Cortés, MD, PhD, of Barcelona’s IOB Institute of Oncology, offers key insights into the findings of the DESTINY-Breast03 study on trastuzumab deruxtecan as a possible new standard of care for metastatic HER2-positive breast cancer, the safety profile of this agent compared with trastuzumab emtansine, and the clinical implications of treatment moving forward.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.